Clinical Briefs in Myelodysplastic Syndrome

The Many Faces of Myelodysplastic Syndromes
The Many Faces of Myelodysplastic Syndromes
CME, CPE
Azra Raza, MD
Release Date: May 22, 2015
Expiration Date: May 22, 2016

In this focused presentation, Dr. Azra Raza discusses the evolution of various classification systems, and how they may be used in combination with prognostic scoring systems and molecular classification to support tailoring of therapeutic strategies for the individual patient with MDS and, ultimately, improved outcomes.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation.
View Only, CE ExpiredView Only, No Credit
 
Appropriate Use of Iron Chelation in Myelodysplastic Syndromes
Appropriate Use of Iron Chelation in Myelodysplastic Syndromes
CME, CPE
Azra Raza, MD
Release Date: May 22, 2015
Expiration Date: May 22, 2016

In this focused presentation, Dr. Azra Raza discusses the physiologic basis of iron overload in patients with MDS, how to measure iron overload, and which patients will benefit from iron chelation therapy (ICT)

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation.
View Only, CE ExpiredView Only, No Credit
 
Myelodysplastic Syndromes: Practical Tools for Management
Myelodysplastic Syndromes: Practical Tools for Management
CME, CPE
Sandra Kurtin, RN, MS, AOCN©, ANP-C
Release Date: February 06, 2015
Expiration Date: February 06, 2016

Sandra Kurtin, RN, MS, AOCN©, ANP-C, discusses practical tools for managing myelodysplastic syndromes including symptom management.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation.
View Only, CE ExpiredView Only, No Credit
 
Effective Assessment of Response to Therapy in Patients with MDS
Effective Assessment of Response to Therapy in Patients with MDS
CME, CPE
Stephen D. Nimer, MD
Release Date: October 17, 2014
Expiration Date: October 17, 2015

Dr. Stephen Nimer discusses critical elements that must be considered when patient response to treatment is assessed, and therapeutic choices clinicians face based on the results of these assessments.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation.
View Only, CE ExpiredView Only, No Credit
 
Continuing Therapy in Myelodysplastic Syndrome
Continuing Therapy in Myelodysplastic Syndrome
CME, CPE
Stuart L. Goldberg, MD
Release Date: August 13, 2014
Expiration Date: August 13, 2015

When should you expect to see a response to treatment? At what point should treatment be stopped? Dr. Goldberg discusses the current factors that determine response, treatment regimens, and the additional ongoing clinical trials associated with improved response.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation.
View Only, CE ExpiredView Only, No Credit
 
Risk Assessment for Myelodysplastic Syndromes
Risk Assessment for Myelodysplastic Syndromes
CME, CPE
Rami Komrokji, MD
Release Date: May 15, 2014
Expiration Date: May 15, 2015

Join world-renowned expert Dr. Rami S. Komrokji in a discussion of the most commonly used prognostic systems for MDS with real-world case presentations illustrating their use as prognostic tools and their role in individualized treatment planning.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation.
View Only, CE ExpiredView Only, No Credit
 

Managing MDS would like to recognize and thank Celgene Corporation for their educational support of ManagingMDS.com

©2017 MediCom Worldwide, Inc. All rights reserved